Woodmont Investment Counsel’s Pacira BioSciences PCRX Stock Holding History

Woodmont Investment Counsel’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-7,300	Closed	-$236K	–	186
2016 Q4	$236K	Buy	+7,300	New	+$244K	0.07%	174
2015 Q3	–	Sell	-3,511	Closed	-$248K	–	563
2015 Q2	$248K	Sell	3,511 -7,226	-67%	-$569K	0.07%	168
2015 Q1	$954K	Buy	10,737 +4,700	+78%	+$477K	0.29%	90
2014 Q4	$535K	Sell	6,037 -2,400	-28%	-$227K	0.16%	127
2014 Q3	$818K	Buy	8,437 +2,700	+47%	+$263K	0.23%	119
2014 Q2	$527K	Buy	+5,737	New	+$437K	0.15%	148

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Woodmont Investment Counsel's PCRX Position: Q1 2017 in Review

Woodmont Investment Counsel sold out of Pacira BioSciences (PCRX) in Q1 2017, closing a stake of 7,300 shares — an estimated $236K sold.

Woodmont Investment Counsel first reported a position in PCRX in Q2 2014 and held it in 6 quarters. The position peaked at $954K in Q1 2015. 192 funds tracked by Wall St. Rank hold PCRX as of Q1 2017.

Woodmont Investment Counsel reported no remaining Pacira BioSciences position as of Q1 2017 after selling out during the quarter.
Woodmont Investment Counsel sold 7,300 Pacira BioSciences shares in Q1 2017, an estimated $236K.
Woodmont Investment Counsel first reported a position in Pacira BioSciences in Q2 2014 and held it in 6 quarters.
Woodmont Investment Counsel's Pacira BioSciences position peaked at $954K in Q1 2015.
192 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2017.

Based on Woodmont Investment Counsel's 13F filing for Q1 2017, filed 12 May 2017.